DK1610791T3 - Implanterbar polymer anordning for vedvarende frigivelse af dopamin-agonist - Google Patents

Implanterbar polymer anordning for vedvarende frigivelse af dopamin-agonist

Info

Publication number
DK1610791T3
DK1610791T3 DK04758809.0T DK04758809T DK1610791T3 DK 1610791 T3 DK1610791 T3 DK 1610791T3 DK 04758809 T DK04758809 T DK 04758809T DK 1610791 T3 DK1610791 T3 DK 1610791T3
Authority
DK
Denmark
Prior art keywords
dopamine agonist
sustained release
release device
treatment
implantable polymer
Prior art date
Application number
DK04758809.0T
Other languages
English (en)
Inventor
Rajesh A Patel
Louis R Bucalo
Lauren Costantini
Sofie Kleppner
Original Assignee
Titan Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Titan Pharmaceuticals Inc filed Critical Titan Pharmaceuticals Inc
Application granted granted Critical
Publication of DK1610791T3 publication Critical patent/DK1610791T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/048—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/12—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L31/125—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/146—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/606—Coatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2420/00—Materials or methods for coatings medical devices
    • A61L2420/04—Coatings containing a composite material such as inorganic/organic, i.e. material comprising different phases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Dispersion Chemistry (AREA)
  • Composite Materials (AREA)
  • Materials Engineering (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Polymers & Plastics (AREA)
DK04758809.0T 2003-03-31 2004-03-31 Implanterbar polymer anordning for vedvarende frigivelse af dopamin-agonist DK1610791T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45931503P 2003-03-31 2003-03-31
PCT/US2004/010270 WO2004089375A1 (en) 2003-03-31 2004-03-31 Implantable polymeric device for sustained release of dopamine agonist

Publications (1)

Publication Number Publication Date
DK1610791T3 true DK1610791T3 (da) 2011-05-09

Family

ID=33159641

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04758809.0T DK1610791T3 (da) 2003-03-31 2004-03-31 Implanterbar polymer anordning for vedvarende frigivelse af dopamin-agonist

Country Status (20)

Country Link
US (5) US20050031667A1 (da)
EP (1) EP1610791B1 (da)
JP (3) JP5064794B2 (da)
KR (1) KR101152183B1 (da)
CN (2) CN102772357B (da)
AT (1) ATE499100T1 (da)
AU (1) AU2004228017C1 (da)
CA (1) CA2520613C (da)
CY (1) CY1111465T1 (da)
DE (1) DE602004031512D1 (da)
DK (1) DK1610791T3 (da)
ES (1) ES2359977T3 (da)
IL (1) IL171115A (da)
MX (1) MXPA05010450A (da)
NZ (1) NZ542548A (da)
PL (1) PL1610791T3 (da)
PT (1) PT1610791E (da)
SI (1) SI1610791T1 (da)
WO (1) WO2004089375A1 (da)
ZA (1) ZA200507877B (da)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
DE10053397A1 (de) * 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
MXPA04005572A (es) * 2001-12-11 2004-12-06 Univ Virginia Uso de pramipexol para tratamiento de esclerosis lateral amiotrofica.
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
PT2561860T (pt) 2002-05-31 2018-05-08 Titan Pharmaceuticals Inc Dispositivo polimérico implantável para a libertação prolongada de buprenorfina
CA2520613C (en) 2003-03-31 2012-12-04 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of dopamine agonist
WO2004110400A2 (en) * 2003-05-30 2004-12-23 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of nalmefene
EP2594259A1 (en) 2004-08-04 2013-05-22 Brookwood Pharmaceuticals, Inc. Methods for manufacturing delivery devices and devices thereof
JP5081622B2 (ja) * 2004-09-21 2012-11-28 山▲東緑▼叶制▲薬▼有限公司 ドーパミン受容体アゴニストを含む長時間作用する持続放出製剤、及びそれらの製造方法
US20090156581A1 (en) * 2005-04-15 2009-06-18 Board Of Trustrees Of Michigan State University Aminergic pharmaceutical compositions and methods
US20080234338A1 (en) * 2005-08-15 2008-09-25 University Of Virginia Patent Foundation Neurorestoration With R(+) Pramipexole
PT2010184E (pt) * 2006-04-06 2013-04-03 Nupathe Inc Implantes para o tratamento dos estados associados à dopamina
US8518926B2 (en) * 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
US20070259930A1 (en) * 2006-04-10 2007-11-08 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
KR20090021169A (ko) * 2006-05-16 2009-02-27 크놉 뉴로사이언시스 인코포레이티드 Ｒ(+) 및 ｓ(-) 프라미펙솔을 포함하는 조성물 및 이의 사용 방법
WO2007139744A2 (en) * 2006-05-23 2007-12-06 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine with minimal initial burst
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
CN101715443A (zh) 2007-03-14 2010-05-26 诺普神经科学股份有限公司 手性纯化的取代的苯并噻唑二胺的合成
US8124601B2 (en) * 2007-11-21 2012-02-28 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
CA2709712C (en) 2007-12-20 2016-05-10 Surmodics Pharmaceuticals, Inc. Process for preparing microparticles having a low residual solvent volume
US20090247537A1 (en) * 2008-03-25 2009-10-01 William Dale Overfield Methods for preventing or treating bruxism using dopaminergic agents
WO2010010136A1 (en) * 2008-07-24 2010-01-28 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising pramipexole and an anti-inflammatory agent for the treatment of parkinson's disease
US20110190356A1 (en) * 2008-08-19 2011-08-04 Knopp Neurosciences Inc. Compositions and Methods of Using (R)- Pramipexole
US8188065B2 (en) * 2008-10-02 2012-05-29 Osteogenex Inc. Boldine compounds for promoting bone growth
CN102802418A (zh) * 2009-06-19 2012-11-28 诺普神经科学股份有限公司 用于治疗肌萎缩性侧索硬化的组合物和方法
US8263581B2 (en) 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8513259B2 (en) 2009-07-03 2013-08-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US20120191039A1 (en) 2009-07-31 2012-07-26 Ascendis Pharma A/S Carrier linked pramipexole prodrugs
WO2011012723A1 (en) 2009-07-31 2011-02-03 Ascendis Pharma As Injectable sustained release compositions comprising a pramipexole prodrug
JP5675820B2 (ja) * 2009-09-22 2015-02-25 エボニック コーポレイションＥｖｏｎｉｋ Ｃｏｒｐｏｒａｔｉｏｎ 様々な生物活性剤担持構成を有するインプラントデバイス
EP2496080A4 (en) * 2009-11-02 2013-05-15 Nupathe Inc METHOD FOR THE TREATMENT OF MORBUS PARKINSON
PL2547332T3 (pl) * 2010-03-16 2019-07-31 Titan Pharmaceuticals, Inc. Heterogeniczne wyroby wszczepialne do podaży leku
US20120021770A1 (en) 2010-07-21 2012-01-26 Naqvi Shamim A System and method for control and management of resources for consumers of information
US9232046B2 (en) 2010-07-21 2016-01-05 Tksn Holdings, Llc System and method for controlling mobile services using sensor information
US9210528B2 (en) 2010-07-21 2015-12-08 Tksn Holdings, Llc System and method for control and management of resources for consumers of information
FR2976809A1 (fr) * 2011-06-27 2012-12-28 Air Liquide Medicament inhalable a base de krypton pour traiter ou prevenir les dyskinesies
FR2976810A1 (fr) * 2011-06-27 2012-12-28 Air Liquide Medicament inhalable a base de neon pour traiter ou prevenir les dyskinesies
FR2976815A1 (fr) * 2011-06-27 2012-12-28 Air Liquide Medicament inhalable a base d'argon pour traiter ou prevenir les dyskinesies
KR102035877B1 (ko) 2011-11-14 2019-10-23 알파시그마 에스.피.에이. 우울증이 있는 대상체를 위한 치료 양생법 선택을 위한 검정법 및 치료 방법
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
KR101558043B1 (ko) * 2012-07-06 2015-10-07 에스케이케미칼주식회사 로티고틴 함유 경피흡수제제
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
ES3043076T3 (en) 2013-07-12 2025-11-24 Areteia Therapeutics Inc Treating elevated levels of eosinophils and/or basophils
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
WO2015023786A1 (en) 2013-08-13 2015-02-19 Knopp Biosciences Llc Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders
ES2871556T3 (es) 2013-08-13 2021-10-29 Knopp Biosciences Llc Composiciones y métodos para el tratamiento de la urticaria crónica
US10698930B2 (en) 2013-08-22 2020-06-30 Sensoriant, Inc. Assignment of application (apps) and relevant services to specific locations, dates and times
WO2015136446A1 (en) 2014-03-11 2015-09-17 Nestec S.A. Methods for selecting antidepressant drug therapy to treat depression
US10390289B2 (en) 2014-07-11 2019-08-20 Sensoriant, Inc. Systems and methods for mediating representations allowing control of devices located in an environment having broadcasting devices
US10614473B2 (en) 2014-07-11 2020-04-07 Sensoriant, Inc. System and method for mediating representations with respect to user preferences
US10824440B2 (en) 2014-08-22 2020-11-03 Sensoriant, Inc. Deriving personalized experiences of smart environments
WO2017053707A1 (en) 2015-09-23 2017-03-30 Sensoriant, Inc. Method and system for using device states and user preferences to create user-friendly environments
KR102637575B1 (ko) * 2016-10-05 2024-02-20 타이탄 파머슈티컬즈 인코퍼레이티드 버스트 방출이 감소된 약물 전달용 이식 가능한 장치
US20180207328A1 (en) * 2017-01-22 2018-07-26 Kamalesh K. Rao Implantable Compositions for Pain Management
AU2019275406B2 (en) 2018-05-24 2024-11-14 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
WO2019226519A1 (en) 2018-05-24 2019-11-28 Celanese EVA Performance Polymers Corporation Implantable device for sustained release of a macromolecular drug compound
WO2019222856A1 (en) 2018-05-24 2019-11-28 Nureva Inc. Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones
CA3139559A1 (en) 2019-05-09 2020-11-12 Apkarian Technologies Llc Methods and compositions for treating pain
EP4132475A4 (en) * 2020-04-10 2024-04-24 Scienture, Inc. Long-acting apomorphine formulations and injectors for therapeutic delivery of the same
WO2022231930A1 (en) 2021-04-26 2022-11-03 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
CN116256439B (zh) * 2021-12-10 2025-11-07 远大医药（中国）有限公司 Hplc检测盐酸多巴胺注射液中焦亚硫酸钠含量的方法
US12582767B2 (en) 2021-12-30 2026-03-24 Taiyo Weber Compressible, minimally invasive implants and related systems and methods
CN117323305B (zh) * 2023-11-07 2024-06-07 杭州沐源生物医药科技有限公司 溴隐亭片剂及其制备方法
WO2025174767A1 (en) * 2024-02-13 2025-08-21 Biraj Investments, Llc Highly loaded implantable devices with high tensile strength for drug delivery

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES335314A1 (es) * 1966-01-06 1967-12-01 Ceskoslovenska Akademie Ved Mejoras introducidas en la preparacion de vehiculos insolubles de sustancias al menos parcialmente solubles, biologicamente activas.
US3717639A (en) * 1967-05-04 1973-02-20 Little Inc A Process for the preparation of 1-(2-nitro-3,4-di-lower-alkoxybenzyl)isoquinolines
US4069307A (en) * 1970-10-01 1978-01-17 Alza Corporation Drug-delivery device comprising certain polymeric materials for controlled release of drug
US3814768A (en) * 1971-11-26 1974-06-04 Lewenstein E 6-methylene-6-desoxy dihydro morphine and codeine derivatives and pharmaceutically acceptable salts
US4450150A (en) * 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US4351337A (en) * 1973-05-17 1982-09-28 Arthur D. Little, Inc. Biodegradable, implantable drug delivery device, and process for preparing and using the same
US3923939A (en) * 1974-06-07 1975-12-02 Alza Corp Process for improving release kinetics of a monolithic drug delivery device
US4148871A (en) * 1977-10-11 1979-04-10 Pitt Colin G Sustained subdermal delivery ofdrugs using poly(ε-caprolactone) and its copolymers
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4543256A (en) * 1982-03-17 1985-09-24 Northeastern University (-)-10,1L Methylenedioxy-N-N-propylnoraporphine and methods employing it for inhibiting the effects of epileptic seizures and for prevention and treatment of duodenal ulcers
AU8533582A (en) 1981-07-10 1984-01-12 Reckitt & Colman Products Limited Stable solutions of buprenorphine
DK119884A (da) 1983-03-18 1984-09-19 Lilly Co Eli Fast, cylindrisk, subkutan implantation og dens anvendelse
US4725442A (en) * 1983-06-17 1988-02-16 Haynes Duncan H Microdroplets of water-insoluble drugs and injectable formulations containing same
US4622219A (en) * 1983-06-17 1986-11-11 Haynes Duncan H Method of inducing local anesthesia using microdroplets of a general anesthetic
US4535157A (en) * 1983-11-01 1985-08-13 Key Pharmaceuticals, Inc. Process for making 6-desoxy-6-methylenenaloxone and 6-desoxy-6-methylenenaltrexone
US4818542A (en) * 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
EP0391893B1 (en) 1983-11-14 1993-08-25 The University of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US4599342A (en) * 1984-01-16 1986-07-08 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
FR2559780B1 (fr) 1984-02-21 1990-05-04 Tech Cuir Centre Systemes biocompatibles implantables a base de collagene permettant la conservation et/ou la culture cellulaires et/ou la liberation controlee de principes actifs
GB8430346D0 (en) * 1984-11-30 1985-01-09 Reckitt & Colmann Prod Ltd Analgesic compositions
US4678809A (en) * 1985-02-01 1987-07-07 Michael Phillips Injectable fomulations of disulfiram for the treatment of alcoholism
US4898733A (en) * 1985-11-04 1990-02-06 International Minerals & Chemical Corp. Layered, compression molded device for the sustained release of a beneficial agent
US4692451A (en) * 1985-12-11 1987-09-08 Trustees Of Tufts College Method for preventing stereotypic behavior in animals
DE3689650T2 (de) 1985-12-17 1994-05-26 United States Surgical Corp Bioresorbierbare Polymere von hohem Molekulargewicht und Implantate davon.
US5316759A (en) * 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
JPS63122620A (ja) * 1986-11-12 1988-05-26 Sanraku Inc ポリ乳酸マイクロスフエア及びその製造方法
US5718921A (en) * 1987-03-13 1998-02-17 Massachusetts Institute Of Technology Microspheres comprising polymer and drug dispersed there within
US5601835A (en) * 1987-04-29 1997-02-11 Massachusetts Institute Of Technology Polymeric device for controlled drug delivery to the CNS
US5114719A (en) * 1987-04-29 1992-05-19 Sabel Bernhard A Extended drug delivery of small, water-soluble molecules
US4883666A (en) * 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
US4861627A (en) * 1987-05-01 1989-08-29 Massachusetts Institute Of Technology Preparation of multiwall polymeric microcapsules
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
ES2054784T3 (es) * 1987-08-08 1994-08-16 Akzo Nv Un metodo para la fabricacion de un implante.
US5156844A (en) * 1987-11-17 1992-10-20 Brown University Research Foundation Neurological therapy system
GB8728294D0 (en) * 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US4882335A (en) * 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
US5236714A (en) * 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
JP2738881B2 (ja) 1989-06-21 1998-04-08 ブラウン ユニバーシティ リサーチ ファウンデイション 神経治療システム
US5750136A (en) * 1989-11-03 1998-05-12 Riker Laboratories, Inc. Bioadhesive composition and patch
US5240711A (en) * 1989-11-29 1993-08-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising as active component buprenorphine
DE3939376C1 (da) 1989-11-29 1991-05-08 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg, 5450 Neuwied, De
US5075341A (en) 1989-12-01 1991-12-24 The Mclean Hospital Corporation Treatment for cocaine abuse
US5219858A (en) * 1990-03-27 1993-06-15 Parnell Pharmaceuticals, Inc. Method and compositions for effecting withdrawal from drug dependency
EP0452111B1 (en) 1990-04-13 1998-07-15 Takeda Chemical Industries, Ltd. Biodegradable high-molecular polymers, production and use thereof
US6517859B1 (en) 1990-05-16 2003-02-11 Southern Research Institute Microcapsules for administration of neuroactive agents
US5086058A (en) 1990-06-04 1992-02-04 Alko Ltd. Method for treating alcoholism with nalmefene
US5128145A (en) * 1990-06-13 1992-07-07 Alza Corporation Dosage form for Parkinson's disease, spasticity and muscle spasms
US5069909A (en) 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US5114718A (en) * 1990-09-20 1992-05-19 The Procter & Gamble Company Sustained release compositions for treating periodontol disease
US5486362A (en) * 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
US5211951A (en) * 1991-07-24 1993-05-18 Merck & Co., Inc. Process for the manufacture of bioerodible poly (orthoester)s and polyacetals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5478577A (en) 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
FR2695826B1 (fr) 1992-09-21 1995-01-06 Theramex Nouvelles compositions pharmaceutiques à base de dérivés de nomégestrol et leurs procédés d'obtention.
US5580876A (en) 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5604194A (en) * 1992-11-17 1997-02-18 The Procter & Gamble Company Stable liquid detergent compositions comprising specific brightener and PVP to inhibit dye transfer
US5298017A (en) * 1992-12-29 1994-03-29 Alza Corporation Layered electrotransport drug delivery system
DE69434304T2 (de) * 1993-03-26 2005-12-29 Merkus, Franciscus Wilhelmus H.M. Pharmazeutische Zusammensetzungen zur intranasalen Verabreichung von Dihydroergotamin
GB9311132D0 (en) * 1993-05-28 1993-07-14 Eisai London Res Lab Ltd Control of cell death
US5650173A (en) * 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
ATE288270T1 (de) * 1993-11-19 2005-02-15 Janssen Pharmaceutica Nv Mikroverkapselte 1,2-benzazole
EP2283821A1 (en) * 1993-11-19 2011-02-16 Alkermes, Inc. Preparation of biodegradable microparticles containing a biologically active agent
JP3720386B2 (ja) 1993-12-27 2005-11-24 住友製薬株式会社 薬物放出制御製剤
HUT75469A (en) * 1994-02-28 1997-05-28 Medinova Med Consulting Gmbh Drug targeting system, method for preparing same and its use
CA2188385C (en) * 1994-04-22 2000-07-11 Ragab El-Rashidy Dosage forms and method for ameliorating male erectile dysfunction
JP2819236B2 (ja) * 1994-05-06 1998-10-30 日東電工株式会社 経皮吸収製剤
US5604198A (en) * 1994-05-12 1997-02-18 Poduslo; Joseph F. Method to enhance permeability of the blood/brain blood/nerve barriers to therapeutic agents
US5633000A (en) * 1994-06-23 1997-05-27 Axxia Technologies Subcutaneous implant
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US6063116A (en) * 1994-10-26 2000-05-16 Medarex, Inc. Modulation of cell proliferation and wound healing
US5562917A (en) * 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
DE69603577T2 (de) * 1995-02-10 1999-11-25 Medtronic, Inc. Verfahren und vorrichtung zur verabreichung von analgetika
IL112834A (en) 1995-03-01 2000-12-06 Yeda Res & Dev Pharmaceutical compositions for controlled release of soluble receptors
US5587381A (en) 1995-03-27 1996-12-24 Sinclair; John D. Method for terminating methadone maintenance through extinction of the opiate-taking responses
US5877224A (en) * 1995-07-28 1999-03-02 Rutgers, The State University Of New Jersey Polymeric drug formulations
CA2182851A1 (en) * 1995-08-15 1997-02-16 August Masaru Watanabe Method for treating substance abuse withdrawal
US6004962A (en) 1995-09-11 1999-12-21 Gooberman; Lance L. Rapid opioid detoxification
US5733565A (en) 1996-02-23 1998-03-31 The Population Council, Center For Biomedical Research Male contraceptive implant
US6004969A (en) 1996-04-15 1999-12-21 National Science Council Transdermal delivery of buprenorphine preparations
US20040024006A1 (en) * 1996-05-06 2004-02-05 Simon David Lew Opioid pharmaceutical compositions
US6271240B1 (en) * 1996-05-06 2001-08-07 David Lew Simon Methods for improved regulation of endogenous dopamine in prolonged treatment of opioid addicted individuals
US20030211157A1 (en) * 1996-05-06 2003-11-13 Simon David Lew Semi-sol delivery blend for water soluble molecules
JPH09330237A (ja) * 1996-06-07 1997-12-22 Toshiba Corp プロセス切り替え装置およびプロセス切り替え方法
US5980948A (en) * 1996-08-16 1999-11-09 Osteotech, Inc. Polyetherester copolymers as drug delivery matrices
BR9605275A (pt) 1996-10-17 1998-07-21 H2T Handheld Technology Ltda Sistema de comunicaçao por infravermelho difuso
US6203813B1 (en) * 1997-01-13 2001-03-20 Lance L. Gooberman Pharmaceutical delivery device and method of preparation therefor
US20010036469A1 (en) * 1997-01-13 2001-11-01 Gooberman Lance L. Opiate antagonist implant and process for preparation therefor
GB9700878D0 (en) 1997-01-17 1997-03-05 Scherer Ltd R P Dosage forms and method for ameliorating male erectile dysfunction
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US5919473A (en) * 1997-05-12 1999-07-06 Elkhoury; George F. Methods and devices for delivering opioid analgesics to wounds via a subdermal implant
US6342250B1 (en) * 1997-09-25 2002-01-29 Gel-Del Technologies, Inc. Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices
CN1204890C (zh) * 1997-12-22 2005-06-08 欧罗赛铁克股份有限公司 防止阿片样物质滥用的方法
TW460599B (en) * 1998-01-14 2001-10-21 Toshiba Corp Method for forming fine wiring pattern
US6007841A (en) 1998-03-13 1999-12-28 Algos Pharmaceutical Corporation Analgesic composition and method for treating pain
US6613358B2 (en) * 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
EP0945133A1 (en) 1998-03-26 1999-09-29 Lipha Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator
US6423345B2 (en) 1998-04-30 2002-07-23 Acusphere, Inc. Matrices formed of polymer and hydrophobic compounds for use in drug delivery
US6011043A (en) * 1998-06-19 2000-01-04 Schering Corporation Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
US6001845A (en) * 1998-06-19 1999-12-14 Schering Corporation Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
US5994363A (en) * 1998-08-24 1999-11-30 Pentech Pharmaceuticals, Inc. Amelioration of apomorphine adverse effects
EP1117441A2 (en) 1998-10-02 2001-07-25 Guilford Pharmaceuticals Inc. Biodegradable terephthalate polyester-poly(phosphonate) and polyester-poly(phosphite) compositions, articles, and methods of using them
KR100383252B1 (ko) 1998-12-17 2003-07-16 주식회사 삼양사 부프레놀핀을함유하는경피투여조성물및이를포함하는패취
US6541021B1 (en) * 1999-03-18 2003-04-01 Durect Corporation Devices and methods for pain management
WO2000072827A2 (en) 1999-05-27 2000-12-07 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
ATE329607T1 (de) * 1999-08-10 2006-07-15 Uab Research Foundation Methode zur behandlung von verletzungen des traumatisierten gehirns mit nicht-steroid entzündungshemmenden medikamenten
KR100730440B1 (ko) 1999-08-27 2007-06-19 브룩우드 파마슈티컬스, 인코포레이티드 주사가능한 부프레노르핀 미세 입자 조성물 및 이의 용도
WO2001043726A1 (en) * 1999-12-16 2001-06-21 Trident Technologies, Llc System and method for extended delivery of a therapeutic agent with its receptor loading dose
AU2002246490A1 (en) * 2000-10-12 2002-07-30 Pharmacia And Upjohn Company Method of treating parkinson's disease
CN1520297A (zh) * 2001-04-26 2004-08-11 ���ߵ���Ƶϵͳ��˾ 包含复合药物(codrugs)的缓释药物传递系统
US20020198574A1 (en) 2001-06-22 2002-12-26 Ron Gumpert Automatic sobriety training and reconditioning system
GB0202900D0 (en) * 2002-02-07 2002-03-27 Laxdale Ltd Novel formulations of drugs
CN1658836A (zh) * 2002-05-07 2005-08-24 控制传输系统公司 形成药物传递装置的方法
PT2561860T (pt) * 2002-05-31 2018-05-08 Titan Pharmaceuticals Inc Dispositivo polimérico implantável para a libertação prolongada de buprenorfina
WO2004054553A1 (en) * 2002-12-13 2004-07-01 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for analgesia
CA2520613C (en) 2003-03-31 2012-12-04 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of dopamine agonist
WO2004110400A2 (en) * 2003-05-30 2004-12-23 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of nalmefene
US20050245541A1 (en) * 2004-03-19 2005-11-03 Elliot Ehrich Methods for treating alcoholism
WO2007139744A2 (en) * 2006-05-23 2007-12-06 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine with minimal initial burst

Also Published As

Publication number Publication date
CA2520613A1 (en) 2004-10-21
US20090162412A1 (en) 2009-06-25
MXPA05010450A (es) 2005-11-04
EP1610791A1 (en) 2006-01-04
US8852623B2 (en) 2014-10-07
JP5608581B2 (ja) 2014-10-15
KR20060015491A (ko) 2006-02-17
AU2004228017C1 (en) 2010-06-03
EP1610791B1 (en) 2011-02-23
NZ542548A (en) 2009-04-30
HK1083682A1 (en) 2006-07-07
HK1177895A1 (en) 2013-08-30
ZA200507877B (en) 2007-01-31
AU2004228017A1 (en) 2004-10-21
JP5064794B2 (ja) 2012-10-31
CY1111465T1 (el) 2015-08-05
PL1610791T3 (pl) 2011-07-29
US20150151029A1 (en) 2015-06-04
ATE499100T1 (de) 2011-03-15
DE602004031512D1 (de) 2011-04-07
KR101152183B1 (ko) 2012-06-15
JP2013213056A (ja) 2013-10-17
SI1610791T1 (sl) 2011-05-31
ES2359977T3 (es) 2011-05-30
US20080311171A1 (en) 2008-12-18
CA2520613C (en) 2012-12-04
US9278163B2 (en) 2016-03-08
CN102772357A (zh) 2012-11-14
US20050031667A1 (en) 2005-02-10
PT1610791E (pt) 2011-05-23
WO2004089375A1 (en) 2004-10-21
CN1777426A (zh) 2006-05-24
IL171115A (en) 2015-10-29
CN102772357B (zh) 2014-12-31
JP2006522149A (ja) 2006-09-28
JP2011087986A (ja) 2011-05-06
US20120258161A1 (en) 2012-10-11

Similar Documents

Publication Publication Date Title
IL171115A (en) An implantable polymeric device for the sustained release of a dopamine agonist
CY1120510T1 (el) Εμφυτευσιμο πολυμερες προϊον για την παρατεταμενη απελευθερωση βουπρενορφινης
MXPA05012768A (es) Dispositivo polimerico implantable para liberacion prolongada de nalmefeno.
WO2007139744A3 (en) Implantable polymeric device for sustained release of buprenorphine with minimal initial burst
MA27523A1 (fr) Formulation retard a liberation controlee
DE602004030522D1 (de) Schicht für kontrollierte Freigabe eines therapeutischen Wirkstoffes
JP2006522149A5 (da)
MXPA05010873A (es) Metodos para el tratamiento de enfermedad de parkinson.
MX2007006214A (es) Un implante para suministro de farmaco intraocular.
GB2465677B (en) Non-systemic delivery of satiogens for use in the treatment of obesity and/or diabetes
MX2010009824A (es) Preparacion solida de desintegracion oral.
SG166093A1 (en) Inhibitors of brutonæs tyrosine kinase
EP4541418A3 (en) Assays for diagnosing and evaluating treatment options for fabry disease
EA201070453A1 (ru) Экструдируемые и экструдированные композиции для доставки биологически активных агентов, способ их получения и способ их использования
ATE416798T1 (de) Medizinprodukt mit gewebeabhängiger arzneimittelelution
BR0316947A (pt) Liberação iontoforética de rotigotina para o tratamento da doença de parkinson
EP1781350A4 (en) METHOD FOR PRODUCING COATED MEDICAL DEVICES
MX2010001449A (es) Bromhidrato de bupropion y aplicaciones terapeuticas.
MX2009011641A (es) Agentes de liberacion para dispositivo de implante y metodos para utilizar los mismos.
DK1781277T3 (da) Kombinationssammensætning, der omfatter Ibuprofen og Paracetamol
WO2008105038A1 (ja) 抗真菌症用貼付剤
FR2886851B1 (fr) Composition a base d'une avermectine et de metronidazole notamment pour le traitement de la rosacee
TW200637584A (en) External skin agent for preventing inflammation
MX2009001231A (es) Implantes subcutaneos que liberan un principio activo durante un periodo de tiempo extendido.
MX2007007099A (es) Implante formado in situ para animales.